We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microchip to Replace Research Animals

By Biotechdaily staff writers
Posted on 04 Oct 2005
To reduce the number of animals used in the development of new drugs, researchers have developed a microchip that serves as an in vivo surrogate, reducing the use of animals, speeding drug development, lowering costs, and increasing the efficiency of preclinical testing.

The 22 mm microfluidic circuit, developed by scientists at Cornell University (Ithaca, NY, USA), is designed to assess the effects of a new drug compound in animals or humans in a high-throughput manner. More...
The idea is to run the chip as though it were a rat or dog and to be able to tell if this particular animal is going to be appropriate for further testing.

The microfluidic unit contains an arrangement of interconnected "organ” or "tissue” compartments. Each contains a culture of living cells from animals or humans to mimic the function of particular organs and tissues, such as liver, heart, lung, or fat cells. The compartments are connected by micro channels through which a blood substitute, or culture medium, circulates. The test drug is added to this culture medium and circulates around the device. Its effects on the cells within each compartment can then be measured.

"What we are trying to do is to mimic what goes on in the body on a micro scale,” explained Dr. Leslie Benet, professor of biopharmaceutical sciences at the University of California San Francisco (USA; www.ucsf.edu). Dr. Benet believes the chip will save a lot of animal studies but will not eliminate them. "At the moment, we don't know which animal is going to be useful. So the industry often carries out animal tests that turn out not to be predictive at all.”

The chip should provide data on how a drug is handled by the body, how it is eliminated, and how it is metabolized. According to Dr. Benet, by assessing a drug's effects on different tissues and by being able to mimic the normal interplay of enzymes and transporters, the microchip should be more efficient than standard cell culture experiments. Dr. Benet is chairman of the scientific advisory board for a new corporation founded to commercialize the microchip.




Related Links:
U. California, SF
Cornell Univ

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.